|Brand name(s), other common name(s)||Bosulif®|
|Drug type||Tyrosine kinase inhibitor (TKI)|
|How the drug is given||By mouth|
Bosutinib is FDA approved for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
The safety and effectiveness of bosutinib was evaluated in a single clinical trial that enrolled 546 adult patients who had chronic, accelerated or blast phase CML. All patients had disease that progressed after treatment with imatinib or imatinib followed by dasatinib and/or nilotinib, or who could not tolerate the side effects of prior therapy. All patients in the trial were treated with bosutinib.
Side effects needing medical attention:Diarrhea; nausea; vomiting; abdominal pain; low blood cell counts; rash; anemia; fever; fatigue; headache; dizziness; cough; anaphylactic shock; myelosuppression; fluid retention; liver damage; rash.